Metabolic syndrome and vascular risk in patients with peripheral arterial occlusive disease

Journal of Vascular Surgery

Volumn 50, Issue 1, 2009, Pages 61-69

  Vlek, Anne L M ^a   van der Graaf, Yolanda ^a   Sluman, Maayke A ^b   Moll, Frans L ^a   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STROKE; SURVIVAL RATE; WAIST CIRCUMFERENCE; WEIGHT CONTROL;

AGED; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 67649194374     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.12.070     Document Type: Article

References (44)

1. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., and Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
2. Diehm C., Schuster A., Allenberg J.R., Darius H., Haberl R., Lange S., et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172 (2004) 95-105
3. Gornik H.L., and Beckman J.A. Cardiology patient page. Peripheral arterial disease. Circulation 111 (2005) e169-e172
4. Ouriel K. Peripheral arterial disease. Lancet 358 (2001) 1257-1264
5. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
6. Gorter P.M., Olijhoek J.K., van der Graaf Y., Algra A., Rabelink T.J., Visseren F.L., and SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 173 (2004) 363-369
7. Brevetti G., Schiano V., Sirico G., Giugliano G., Laurenzano E., and Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 44 (2006) 101-107 discussion 107
8. Olijhoek J.K., van der Graaf Y., Banga J.D., Algra A., Rabelink T.J., Visseren F.L., and SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 25 (2004) 342-348
9. Girman C.J., Rhodes T., Mercuri M., Pyörälä K., Kjekshus J., Pedersen T.R., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
10. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., and Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
11. Levantesi G., Macchia A., Marfisi R., Franzosi M.G., Maggioni A.P., Nicolosi G.L., et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 46 (2005) 277-283
12. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29 (2006) 901-907
13. Nigam A., Bourassa M.G., Fortier A., Guertin M.C., and Tardif J.C. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 151 (2006) 514-521
14. Wassink A.M., van der Graaf Y., Olijhoek J.K., Visseren F.L., and SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 29 (2008) 213-223
15. Simons P.C., Algra A., van de Laak M.F., Grobbee D.E., and van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 15 (1999) 773-781
16. Goessens B.M., van der Graaf Y., Olijhoek J.K., Visseren F.L., and SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 45 (2007) 47-54
17. Fontaine R., Kim M., and Kieny R. [Surgical treatment of peripheral circulation disorders.]. [Article in German.]. Helv Chir Acta 21 (1954) 499-533
18. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
19. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
20. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
21. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S5-S20
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
23. Reaven G.M. Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol Metab Clin North Am 37 (2008) 581-601 vii-viii
24. Risérus U., Arnlöv J., and Berglund L. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 30 (2007) 2928-2933
25. Duncan G.E., Perri M.G., Theriaque D.W., Hutson A.D., Eckel R.H., and Stacpoole P.W. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 26 (2003) 557-562
26. Ross R. Does exercise without weight loss improve insulin sensitivity?. Diabetes Care 26 (2003) 944-945
27. Laakso M. Gene variants, insulin resistance, and dyslipidaemia. Curr Opin Lipidol 15 (2004) 115-120
28. Hofman P.L., Cutfield W.S., Robinson E.M., Bergman R.N., Menon R.K., Sperling M.A., and Gluckman P.D. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab 82 (1997) 402-406
29. Daly C.A., Hildebrandt P., Bertrand M., Ferrari R., Remme W., Simoons M., et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 93 (2007) 1406-1411
30. Wassink A.M., Olijhoek J.K., and Visseren F.L. The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest 37 (2007) 8-17
31. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., and Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 (2005) 3066-3072
32. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26 (2003) 1251-1257
33. Golden S.H., Folsom A.R., Coresh J., Sharrett A.R., Szklo M., and Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 51 (2002) 3069-3076
34. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., and Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152 (2000) 897-907
35. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., and Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
36. Hillier T.A., Fagot-Campagna A., Eschwège E., Vol S., Cailleau M., Balkau B., and D.E.S.I.R. Study group. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the D.E.S.I.R. cohort. Int J Epidemiol 35 (2006) 190-196
37. Lloyd-Jones D.M., Liu K., Colangelo L.A., Yan L.L., Klein L., Loria C.M., et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 115 (2007) 1004-1011
38. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
39. Wilson P.W., and Grundy S.M. The metabolic syndrome: a practical guide to origins and treatment: Part II. Circulation 108 (2003) 1537-1540
40. Schaefer E.J., and Asztalos B.F. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8 (2006) 41-49
41. Balkau B., Vernay M., Mhamdi L., Novak M., Arondel D., Vol S., et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 29 (2003) 526-532
42. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357 (2001) 995-1001
43. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
44. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928